Spruce Biosciences provides cash update; adult CAH trials enrollment complete; topline data expected March 2024

SPRUCE BIOSCIENCES, INC.

Cash and equivalents ~$96M as of Dec 31, 2023; 41.0M shares outstanding.
CAHmelia-203 (N=96) and CAHptain-205 (N=30) enrollment complete, surpassing targets.
CAHmelia-204 enrollment to finish Jan 2024 (N~98); topline results from CAHmelia-203 and CAHptain-205 expected March 2024.
Baseline characteristics: CAHmelia-203 mean A4 1,149 ng/dL on 27 mg/day GC; CAHmelia-204 mean A4 214 ng/dL on 35 mg/day GC.
Cash runway into first half of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.